Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Possible Risk of Raised IOP with Lucentis

October 25, 2011 8:07 am | News | Comments

Two major drug trials concluded there was little risk from a drug aimed at age-related macular degeneration. Yet an ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye.


Tube Label Sets

October 25, 2011 6:23 am | Product Releases | Comments

CILS-9100 cap and tube label sets consist of multiple CILS label shapes and sizes on a single roll/letter size sheet allowing variable data printing (batch numbers, barcodes) inlab, straight from your standard laser or thermal transfer printer.


Primer Digestion

October 25, 2011 6:08 am | Drug Discovery & Development | Product Releases | Comments

GE Healthcare’s ExoStar kit supports researchers by providing a high performance and cost effective product for the enzymatic removal of unincorporated primers and nucleotides from PCR and sequencing reactions.


Almac Increasing Manufacturing Capacity

October 25, 2011 6:02 am | News | Comments

Almac is expanding manufacturing capacity at its European headquarters to over 30 m3. The upgraded facility will include reactor vessels with clean room product isolation and drying equipment to allow API manufacture up to a 600 kg batch size.


Dulera Demonstrates Significant Effects on Lung Function

October 25, 2011 5:58 am | News | Comments

Merck announced results from two 26-week investigational Phase 3 clinical studies evaluating the efficacy and safety of two dose strengths of Dulera in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease.


FDA Approves Leukemia Test

October 25, 2011 5:52 am | News | Comments

The Vysis EGR1 FISH Probe Kit can help physicians determine which patients can be treated with chemotherapy, the first option for AML, and who has more severe disease and may require a stem cell transplant.


Generic Zyprexa Approved by FDA

October 25, 2011 5:49 am | News | Comments

Federal health officials approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.


FDA: Studies Do Not Tie Chantix to Mental Problems

October 25, 2011 5:47 am | by Matthew Perrone | News | Comments

Federal health officials said that Pfizer's anti-smoking drug Chantix did not increase psychiatric problems like depression and suicidal thoughts in two studies, though the findings are not definitive.


Generic Lovenox Launching in 4Q

October 25, 2011 5:44 am | News | Comments

Momenta Pharmaceuticals Inc. said that its partner Sandoz's launch of a generic version of the blood thinner Lovenox will trigger royalty payments when Sandoz starts selling the drug during the fourth quarter.


Novartis Cutting 2,000 Jobs

October 25, 2011 5:42 am | News | Comments

Swiss pharmaceutical giant Novartis AG said it will cut 2,000 jobs as drug prices come under pressure from governments seeking to reduce health care budgets.


Redefining Optical Imaging of Biological Samples

October 24, 2011 12:54 pm | News | Comments

For modern biologists, the ability to capture high-quality, three-dimensional images of living tissues or organisms over time is necessary to answer problems in areas ranging from genomics to neurobiology and developmental biology.

Making Internal Organs Visible With Protein

October 24, 2011 12:50 pm | News | Comments

Researchers at Albert Einstein College of Medicine developed the first fluorescent protein that enables scientists to see the internal organs of living animals without the need for a scalpel.

View of Inflammation, Cancer in Imaging Agents

October 24, 2011 12:35 pm | News | Comments

A series of novel imaging agents could make it possible to "see" tumors in their earliest stages, before they turn deadly.

Prasco Selected as Eli Lilly’s Generics Partner

October 24, 2011 12:32 pm | News | Comments

Prasco Laboratories signed a marketing and distribution agreement with Eli Lilly and Company to market the generic version of Zyprexa tablets and Zyprexa Zydis orally disintegrating tablets.


Newron Regains Rights for Safinamide

October 24, 2011 12:28 pm | News | Comments

Newron Pharmaceuticals announced that Merck Serono is returning global rights for safinamide in 180 days.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.